一位85岁的男性患有晚期转移、去势抵抗型前列腺癌，进行了8个周期的177Lu-前列腺特异性膜抗原（PSMA）-617放射性配基治疗（RLT）后出现病情进展，接受了1个周期的161Tb-PSMA RLT。这一次6.5 GBq的161Tb-PSMA-617剂量管理取得了惊人的部分缓解效果，血清前列腺特异性抗原（PSA）下降了53.4%（从474 ng/mL降至221 ng/mL），同时在PSMA PET/CT成像中肿瘤负担也有所减轻。该病例提供了将161Tb-PSMA RLT应用于转移性去势抵抗型前列腺癌的治疗潜力的惊人初步证据，即使是在经历了广泛的177Lu-基础RLT治疗后都能清晰地表现出来。161Tb标记的PSMA配体因此可能是标准PSMA RLT的有前途的替代品。Copyright © 2023 Wolters Kluwer Health，Inc.版权所有。

An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) received 1 cycle of 161Tb-PSMA RLT. This one administration of 6.5 GBq 161Tb-PSMA-617 resulted in impressive partial remission with a PSA decline by 53.4% (from 474 to 221 ng/mL) and a concomitant decrease in tumor burden on PSMA PET/CT imaging. The presented case provides stunning initial evidence of the therapeutic potential of 161Tb-PSMA RLT in metastatic castration-resistant prostate cancer, even in patients progressing after extensive 177Lu-based RLT. 161Tb-labeled PSMA ligands may thus offer a promising alternative to standard PSMA RLT.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.